BioRay Pharmaceutical Co., Ltd.
BioRay Pharmaceutical Co., Ltd.
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Not yet recruiting | Phase 3 | 2026-09-21 | NCT07830433 | |
| A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2026-08-07 | NCT07753590 | |
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-02 | NCT07480863 | |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Hyperuricemia, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Not yet recruiting | Phase 2 | 2026-03-27 | NCT07498647 | |
| Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies | Advanced Gynecological Malignancies | Not yet recruiting | Phase 2 | 2025-12-31 | NCT07311538 | |
| A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies | Advanced Malignancies | Recruiting | Phase 1 | 2025-12-30 | NCT06038058 | |
| A Study of BR111 in Patients With Advanced Malignancies | Advanced Malignancies | Recruiting | Phase 1 | 2025-11-21 | NCT06937957 | |
| Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-11-21 | NCT04514419 | |
| A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Active, not recruiting | Phase 2 | 2025-11-20 | NCT06642909 |